
Kala Pharmaceuticals KALA
$ 2.73
-9.6%
Kala Pharmaceuticals Interest Expense | KALA
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense Kala Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5.15 M | - | 5.81 M | 7.27 M | 8.38 M | 8.59 M | 8.48 M | 3.31 M | 1.02 M | 767 K | 604 K | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 8.59 M | 604 K | 4.94 M |
Quarterly Interest Expense Kala Pharmaceuticals
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 107 K | - | -112 K | - | - | - | - | - | 1.46 M | - | -2.16 M | -119 K | 1.47 M | - | 1.45 M | 2.21 M | 2.04 M | - | 2.07 M | 2.09 M | 2.14 M | - | 2.16 M | 2.13 M | 2.13 M | - | 2.18 M | 2.06 M | 2.09 M | - | 432 K | 414 K | 367 K | - | 212 K | 208 K | 198 K | - | 186 K | 186 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2.21 M | -2.16 M | 1.06 M |
Interest Expense of other stocks in the Biotechnology industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Kodiak Sciences
KOD
|
13 K | $ 97.05 | -0.87 % | $ 5.16 B | ||
|
Karyopharm Therapeutics
KPTI
|
152 K | $ 0.02 | -56.5 % | $ 219 | ||
|
FSD Pharma
HUGE
|
9.34 K | - | 5743.5 % | $ 69.7 M | ||
|
BioAtla
BCAB
|
225 K | $ 1.74 | 0.64 % | $ 102 M | ||
|
Catalyst Pharmaceuticals
CPRX
|
25.7 M | - | - | $ 3.85 B | ||
|
UroGen Pharma Ltd.
URGN
|
-284 K | $ 28.91 | -8.89 % | $ 1.39 B | ||
|
Catalyst Biosciences
CBIO
|
-1.5 M | $ 13.01 | 0.74 % | $ 1.16 B | ||
|
ARCA biopharma
ABIO
|
-12 K | - | 1052.0 % | $ 415 M | ||
|
ADiTx Therapeutics
ADTX
|
15.8 K | - | - | $ 374 | ||
|
AgeX Therapeutics
AGE
|
51 K | - | -10.17 % | $ 12.2 K | ||
|
Aeglea BioTherapeutics
AGLE
|
29.5 M | - | - | $ 1.01 B | ||
|
AIkido Pharma
AIKI
|
-5.79 M | - | 1.93 % | $ 17.4 M | ||
|
Aileron Therapeutics
ALRN
|
48 K | - | 10.36 % | $ 9.8 M | ||
|
AlloVir
ALVR
|
1.44 M | - | 4.14 % | $ 49.1 M | ||
|
Apellis Pharmaceuticals
APLS
|
-133 K | - | - | $ 5.18 B | ||
|
Athira Pharma
ATHA
|
1.24 M | - | - | $ 269 M | ||
|
AVROBIO
AVRO
|
-119 K | - | 1083.1 % | $ 745 M | ||
|
Brainstorm Cell Therapeutics
BCLI
|
-93 K | - | -2.5 % | $ 5.88 M | ||
|
BeiGene, Ltd.
BGNE
|
-42.6 M | - | 0.49 % | $ 251 B | ||
|
EyePoint Pharmaceuticals
EYPT
|
11.8 M | $ 0.23 | -12.11 % | $ 16.8 K | ||
|
Cara Therapeutics
CARA
|
7.16 M | - | -3.03 % | $ 260 M | ||
|
ChromaDex Corporation
CDXC
|
661 K | - | -0.88 % | $ 598 M | ||
|
Caladrius Biosciences
CLBS
|
-145 K | - | -16.75 % | $ 25.8 M | ||
|
Cyclacel Pharmaceuticals
CYCC
|
31 K | - | -5.98 % | $ 34.1 M | ||
|
Diffusion Pharmaceuticals
DFFN
|
-8.33 K | - | 11.68 % | $ 8.97 M | ||
|
Eloxx Pharmaceuticals
ELOX
|
41 K | - | -5.68 % | $ 8.28 M | ||
|
Enochian Biosciences
ENOB
|
-127 K | - | - | $ 40.5 M | ||
|
Esperion Therapeutics
ESPR
|
3.49 M | - | - | $ 661 M | ||
|
Evofem Biosciences
EVFM
|
2.37 M | - | 7.55 % | $ 38.1 M | ||
|
Eyenovia
EYEN
|
390 K | - | 49.81 % | $ 13.2 M | ||
|
FibroGen
FGEN
|
8.76 M | - | - | $ 889 M | ||
|
Homology Medicines
FIXX
|
1.18 M | - | 0.77 % | $ 53.4 M | ||
|
Amicus Therapeutics
FOLD
|
10.2 M | - | - | $ 4.47 B | ||
|
Frequency Therapeutics
FREQ
|
5.23 M | - | - | $ 528 M | ||
|
Galecto
GLTO
|
1.17 M | - | - | $ 762 M | ||
|
GlycoMimetics
GLYC
|
651 K | - | 9357.83 % | $ 1.01 B | ||
|
Graybug Vision
GRAY
|
268 K | - | -11.23 % | $ 9.65 M | ||
|
Galera Therapeutics
GRTX
|
11.4 M | - | -32.59 % | $ 7.61 M | ||
|
Happiness Biotech Group Limited
HAPP
|
263 K | - | 1.35 % | $ 17.8 M | ||
|
Novavax
NVAX
|
40.6 M | $ 7.47 | -3.24 % | $ 1.21 B | ||
|
Hepion Pharmaceuticals
HEPA
|
9.46 K | - | -18.79 % | $ 39.3 K | ||
|
Hoth Therapeutics
HOTH
|
27.1 K | - | - | $ 18.8 M | ||
|
IMARA
IMRA
|
-49 K | - | 15.96 % | $ 663 M | ||
|
KalVista Pharmaceuticals
KALV
|
8.56 M | - | - | $ 1.45 B | ||
|
KemPharm
KMPH
|
1.5 M | - | -0.34 % | $ 200 M | ||
|
Kezar Life Sciences
KZR
|
1.55 M | - | - | $ 53.3 M | ||
|
Lixte Biotechnology Holdings
LIXT
|
9.16 K | - | - | $ 63.4 M |